Sanofi And AstraZeneca Still Lead In RSV But Pfizer Has Chance To Challenge

Pandemic Affected Trial Results

 
• By Andrew McConaghie
  
RSV patient
Cases of RSV have rebounded after the pandemic lockdowns were lifted • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip